Entera Bio Ltd. ENTXW 深 沪
交易中 03-30 10:11:01 美东时间
0.0012
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0012
- 总市值 2.85万
- 52周最高 0.328
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2373.86万
- 历史最高 1.90
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
今天 15:29
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Ltd., a leader in oral peptide development, reported financial and business updates for 2025, highlighting progress in its pipeline, including EB613 for osteoporosis, EB612 for hypoparathyroidism, and EB618 for metabolic syndromes. FDA alignment on BMD as a primary endpoint for EB613 was achieved, with Phase 3 plans advancing. The company also expanded collaborations with OPKO Health and reported cash reserves of $14.9 million, despite...
03-27 20:05
Entera Bio Submits Clinical Amendment To FDA Providing Streamlined Phase 3 Protocol, SAP, And Open-Label Extension Synopsis To IND 505(B)(2) Submission To Evaluate EB613; Entera Expects FDA Feedback Within 60 Days
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3
03-04 21:37
Entera Bio Submits Streamlined EB613 Phase 3 Protocol Amendment to FDA
Entera Bio Submits Streamlined EB613 Phase 3 Protocol Amendment to FDA Entera Bio Ltd. said it submitted a clinical amendment to the U.S. Food and Drug Administration for its IND 505(b)(2) program, providing a streamlined Phase 3 protocol, statistical analysis plan and open-label extension synopsis
03-04 21:31
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Entera Bio Ltd. has submitted a streamlined Phase 3 clinical trial protocol for EB613, an oral osteoanabolic therapy for osteoporosis, to the FDA. The trial will assess total hip BMD at 12 months, reducing the target enrollment and accelerating development. The Phase 3 will use the Next-Gen single tablet formulation, replacing the previous multi-tablet version. Topline data is expected in the second half of 2028, approximately one year earlier th...
03-04 13:30
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours
Entera Bio Ltd. shares jumped 15.71% in after-hours trading following a director's purchase of additional shares.
02-19 14:49
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano Entera Bio Ltd. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing names Geno J. Germano as a director of the company. The full filin
02-09 21:50
Entera Bio ernennt Ex-Pfizer-Manager Geno J. Germano zum neuen Aufsichtsratsvorsitzenden
Entera Bio ernennt Ex-Pfizer-Manager Geno J. Germano zum neuen Aufsichtsratsvorsitzenden Entera Bio Ltd. hat die Ernennung von Geno J. Germano, einem ehemaligen Führungskraft von Pfizer, zum neuen Chairman of the Board bekanntgegeben. Germano übernimmt die Position von Gerald Lieberman. Disclaimer:
02-09 21:46
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as its new Chairman, succeeding Gerald Lieberman. Germano, with over three decades of leadership experience in the biopharmaceutical industry, including senior roles at Pfizer and Wyeth, will guide Entera during a pivotal phase as the company advances two oral peptide programs into clinical trials in 2026: a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in...
02-09 13:50
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio Ltd. announced its key milestones for Q1 2026, including submitting the final Phase 3 protocol for EB613 to the FDA, expecting results from the Next-Generation EB613 Phase 1 bridging study, accelerating its hypoparathyroidism program with long-acting PTH variants, and advancing strategic partnerships across its pipeline. The Company remains committed to addressing unmet medical needs in osteoporosis and hypoparathyroidism.
01-21 13:30
